Nifty
:
24773.15
Sensex
:
80787.30
32.15 (0.13%)
76.54 (0.09%)
Nifty
Sensex
:
:
24773.15
80787.30
32.15 (0.13%)
76.54 (0.09%)

Shilpa Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
54/99

BSE: 530549 | NSE: SHILPAMED

NSE BSE
847.75
08-Sep-2025
  • Open
  • High
  • Low
  • Previous Close
  •  838.9
  •  862.9
  •  838.9
  •  844.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  45917
  •  39079447.55
  •  1000
  •  555

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,313.69
  • 74.82
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 8,416.17
  • 0.12%
  • 3.44

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.23%
  • 10.27%
  • 23.21%
  • FII
  • DII
  • Others
  • 11.19%
  • 6.02%
  • 5.08%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.49
  • 4.87
  • 0.18

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.44
  • 1.93
  • 3.66

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -8.04
  • -27.26
  • -19.30

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.27
  • 71.60
  • 81.41

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.63
  • 2.39
  • 2.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.39
  • 23.34
  • 23.63

Earnings Forecasts:

(Updated: 08-09-2025)
Description
2024
2025
2026
2027
Adj EPS
8.01
28.05
39.7
94.83
P/E Ratio
105.84
30.22
21.35
8.94
Revenue
1286.41
1669.9
1969.85
3154.7
EBITDA
317.05
510.8
641.35
1364.6
Net Income
78.29
276.9
389.45
927.3
ROA
2.45
14.2
15.8
P/B Ratio
3.49
3.14
2.74
1.05
ROE
3.75
11.05
13.75
26.49
FCFF
-180.13
145.51
303.73
551.76
FCFF Yield
-1.86
1.5
3.14
5.7
Net Debt
559.22
BVPS
242.65
270.4
309.6
810.12

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
321.46
292.51
9.90%
330.81
291.69
13.41%
319.32
286.76
11.35%
343.80
312.98
9.85%
Expenses
229.82
218.99
4.95%
254.04
221.63
14.62%
238.62
220.53
8.20%
257.79
252.68
2.02%
EBITDA
91.64
73.52
24.65%
76.77
70.06
9.58%
80.69
66.23
21.83%
86.01
60.30
42.64%
EBIDTM
28.51%
25.13%
23.21%
24.02%
25.27%
23.09%
25.02%
19.27%
Other Income
6.38
9.52
-32.98%
7.57
2.49
204.02%
1.13
1.94
-41.75%
4.99
1.81
175.69%
Interest
18.78
23.74
-20.89%
14.49
24.20
-40.12%
11.75
26.22
-55.19%
25.55
23.24
9.94%
Depreciation
28.92
27.11
6.68%
28.79
26.63
8.11%
28.81
26.71
7.86%
28.28
27.79
1.76%
PBT
50.31
32.20
56.24%
12.97
27.85
-53.43%
41.27
15.23
170.98%
37.16
11.08
235.38%
Tax
2.69
14.62
-81.60%
0.77
3.21
-76.01%
9.83
9.46
3.91%
18.83
7.60
147.76%
PAT
47.62
17.58
170.88%
12.21
24.64
-50.45%
31.44
5.77
444.89%
18.33
3.48
426.72%
PATM
14.81%
6.01%
3.69%
8.45%
9.85%
2.01%
5.33%
1.11%
EPS
4.79
1.44
232.64%
1.48
2.82
-47.52%
3.25
0.53
513.21%
1.83
0.19
863.16%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
1,315.39
1,151.60
1,050.11
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
613.80
Net Sales Growth
11.10%
9.66%
-8.33%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
 
Cost Of Goods Sold
397.07
407.24
416.04
383.22
270.73
277.73
257.03
355.87
371.81
366.19
323.16
Gross Profit
918.32
744.36
634.07
762.30
630.40
630.18
476.36
432.95
407.36
350.25
290.63
GP Margin
69.81%
64.64%
60.38%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
Total Expenditure
980.27
915.53
961.84
948.32
729.43
693.39
579.39
637.60
617.55
556.44
487.38
Power & Fuel Cost
-
52.41
56.79
52.43
40.25
38.76
33.57
28.86
26.30
21.90
19.29
% Of Sales
-
4.55%
5.41%
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
Employee Cost
-
281.49
286.39
264.49
235.31
196.59
176.40
149.35
127.87
90.09
82.30
% Of Sales
-
24.44%
27.27%
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
Manufacturing Exp.
-
82.69
110.32
124.11
91.29
79.19
61.23
59.96
52.55
45.35
36.55
% Of Sales
-
7.18%
10.51%
10.83%
10.13%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
General & Admin Exp.
-
44.36
46.86
71.58
47.71
70.26
27.20
22.50
16.95
14.11
10.64
% Of Sales
-
3.85%
4.46%
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
Selling & Distn. Exp.
-
20.91
18.56
18.02
18.63
10.40
6.72
6.37
4.75
7.27
5.99
% Of Sales
-
1.82%
1.77%
1.57%
2.07%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
Miscellaneous Exp.
-
26.42
26.89
34.49
25.51
20.47
17.23
14.68
17.32
11.54
5.99
% Of Sales
-
2.29%
2.56%
3.01%
2.83%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
EBITDA
335.11
236.07
88.27
197.20
171.70
214.52
154.00
151.23
161.61
159.99
126.42
EBITDA Margin
25.48%
20.50%
8.41%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
Other Income
20.07
16.59
31.41
20.90
40.09
22.22
15.56
32.62
29.34
11.36
6.93
Interest
70.57
91.81
58.65
41.17
21.87
4.56
3.68
2.66
3.13
3.93
4.05
Depreciation
114.80
107.87
95.50
79.80
53.98
43.78
42.06
37.22
30.64
23.14
21.41
PBT
141.71
52.99
-34.47
97.13
135.95
188.40
123.82
143.96
157.17
144.28
107.89
Tax
32.12
22.39
-7.36
41.68
48.85
33.49
26.18
33.91
42.04
35.62
35.22
Tax Rate
22.67%
37.87%
21.35%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
PAT
109.60
31.88
-32.48
60.66
147.78
156.50
120.28
112.43
113.71
109.84
73.69
PAT before Minority Interest
109.59
31.96
-30.92
60.58
146.20
154.91
117.52
110.05
110.59
106.24
72.62
Minority Interest
-0.01
-0.08
-1.56
0.08
1.58
1.59
2.76
2.38
3.12
3.60
1.07
PAT Margin
8.33%
2.77%
-3.09%
5.30%
16.40%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
PAT Growth
112.94%
-
-
-58.95%
-5.57%
30.11%
6.98%
-1.13%
3.52%
49.06%
 
EPS
11.21
3.26
-3.32
6.20
15.11
16.00
12.30
11.50
11.63
11.23
7.53

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
1,808.69
1,783.28
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
Share Capital
8.68
8.68
8.68
8.15
8.15
8.15
8.15
8.01
7.71
7.71
Total Reserves
1,800.01
1,774.60
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
Non-Current Liabilities
589.64
345.12
452.82
561.37
256.94
166.62
153.48
251.26
67.23
154.15
Secured Loans
560.16
242.92
353.49
473.87
164.48
80.39
67.09
141.20
0.03
71.03
Unsecured Loans
0.00
45.90
0.11
0.35
0.53
0.70
1.03
1.30
0.00
31.30
Long Term Provisions
22.43
17.65
19.08
15.48
26.17
21.77
20.32
16.89
13.96
11.75
Current Liabilities
693.35
784.45
611.54
543.29
410.82
253.44
265.84
236.90
222.07
189.06
Trade Payables
174.82
142.80
146.04
67.25
92.55
80.72
103.74
111.86
106.48
75.50
Other Current Liabilities
137.21
276.56
240.13
219.33
142.10
81.62
59.59
28.03
36.49
49.32
Short Term Borrowings
360.73
344.17
202.90
243.40
165.27
86.58
98.12
92.41
74.10
58.47
Short Term Provisions
20.58
20.92
22.46
13.31
10.89
4.52
4.39
4.60
5.00
5.77
Total Liabilities
3,082.94
2,903.93
2,875.50
2,572.16
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
Net Block
1,384.86
1,368.33
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
Gross Block
1,946.75
1,846.68
1,727.09
1,421.10
986.42
853.16
793.24
704.89
582.20
476.34
Accumulated Depreciation
561.89
478.35
385.25
310.57
335.98
295.15
259.04
212.96
188.79
160.28
Non Current Assets
2,206.12
2,134.37
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
576.77
Capital Work in Progress
718.78
655.33
506.18
541.29
666.25
429.12
209.85
140.51
91.90
221.62
Non Current Investment
39.91
42.66
34.23
21.22
10.45
2.25
20.79
27.99
34.15
0.19
Long Term Loans & Adv.
53.32
56.53
93.90
43.10
32.42
48.75
37.47
77.09
51.86
38.74
Other Non Current Assets
9.25
11.52
12.15
13.46
5.78
26.84
24.86
4.80
5.36
0.16
Current Assets
876.83
769.55
887.19
818.99
623.85
545.06
671.97
729.88
354.21
327.61
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
119.54
224.62
59.63
65.35
Inventories
344.93
319.82
355.24
316.84
226.43
187.67
188.71
190.00
134.23
130.78
Sundry Debtors
392.05
324.35
386.33
217.50
246.79
203.73
220.27
170.93
125.43
81.37
Cash & Bank
30.44
21.56
34.11
123.11
44.56
94.54
73.83
100.39
11.03
18.42
Other Current Assets
109.42
15.53
9.36
98.73
106.06
59.12
69.62
43.95
23.90
31.69
Short Term Loans & Adv.
90.60
88.29
102.16
62.81
29.25
14.08
43.54
21.95
8.90
4.91
Net Current Assets
183.48
-14.89
275.66
275.69
213.04
291.62
406.13
492.98
132.14
138.55
Total Assets
3,082.95
2,903.92
2,875.49
2,548.59
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
135.34
179.92
105.13
46.93
124.38
146.78
44.92
37.48
128.70
68.81
PBT
54.34
-38.28
102.26
196.79
188.40
143.70
136.77
146.49
140.36
107.84
Adjustment
205.77
147.81
109.34
4.03
41.32
20.44
18.83
17.19
20.61
26.46
Changes in Working Capital
-83.62
102.77
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
Cash after chg. in Working capital
176.49
212.30
139.62
94.53
166.57
182.85
85.94
71.08
158.27
94.19
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-41.15
-32.37
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-166.58
-232.61
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
Net Fixed Assets
-17.18
-22.18
384.16
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
Net Investments
-2.53
-6.42
-18.18
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
Others
-146.87
-204.01
-651.48
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
Cash from Financing Activity
46.77
45.80
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
Net Cash Inflow / Outflow
15.53
-6.89
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
8.68
Opening Cash & Equivalents
19.07
25.62
122.85
44.31
34.13
73.83
99.97
7.05
3.61
9.19
Closing Cash & Equivalent
30.43
19.07
25.34
123.34
44.31
34.36
73.83
99.97
6.43
18.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
208.37
205.44
209.93
181.37
163.06
146.89
133.09
123.17
82.91
70.92
ROA
1.07%
-1.07%
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
ROE
1.78%
-1.71%
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
ROCE
5.49%
0.80%
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
Fixed Asset Turnover
0.61
0.59
0.73
0.75
0.99
0.89
1.06
1.22
1.36
1.34
Receivable days
113.53
123.51
98.75
94.03
90.56
105.51
90.20
69.00
52.26
43.99
Inventory Days
105.35
117.32
109.68
110.03
83.24
93.66
87.32
75.49
66.97
74.84
Payable days
142.34
126.70
106.00
107.72
47.69
58.00
61.51
60.89
60.10
62.86
Cash Conversion Cycle
76.54
114.12
102.43
96.33
126.11
141.17
116.00
83.61
59.13
55.97
Total Debt/Equity
0.52
0.45
0.37
0.57
0.29
0.16
0.18
0.24
0.14
0.34
Interest Cover
1.59
0.35
3.48
9.92
42.34
40.09
55.10
49.69
37.07
27.63

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Shilpa Medicare’s arm to form new joint venture company in Saudi Arabia
    28th Aug 2025, 11:11 AM

    The new limited liability company will be majority owned by PPI (70%), with Koanna holding a 30% stake

    Read More
  • Shilpa Medicare - Quarterly Results
    13th Aug 2025, 15:31 PM

    Read More
  • Shilpa Medicare receives CDSCO approval for NorUDCA Tablets
    9th Aug 2025, 15:17 PM

    This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD

    Read More
  • Shilpa Medicare receives EIR with VAI for Bengaluru Unit
    16th Jul 2025, 12:00 PM

    The GMP inspection was conducted from October 24-30, 2024

    Read More
  • Shilpa Medicare receives GMP certification from SFDA for Unit VI facility
    10th Jul 2025, 14:51 PM

    This facility of the company is engaged in the manufacture, testing, storage and release of finished dosage forms in the category of Oral Films and Transdermal Patches

    Read More
  • Shilpa Medicare’s arm completes GMP inspection from Brazilian regulatory authority
    7th Jul 2025, 12:51 PM

    The audit was carried out between June 30 to July 4, 2025 and has been concluded with No Critical and No Major observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.